29,13 $
8,29 %vorgestern
Nasdaq, 1. März, 22:00 Uhr
ISIN
US26817R1086
Symbol
DYN
Berichte
Sektor
Industrie

Dyne Therapeutics Inc Aktie News

Neutral
GlobeNewsWire
18 Tage alt
- Presentations will Highlight Initial Data Announced in January 2024 Demonstrating Proof-of-Concept in its DM1 and DMD Programs, Validating the Promise of the FORCE™ Platform and Targeted Delivery to Muscle -
Neutral
GlobeNewsWire
etwa ein Monat alt
WALTHAM, Mass., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced that management is scheduled to present at the following investor conferences in February:
Positiv
InvestorPlace
etwa ein Monat alt
While investors should probably direct the majority of their market-earmarked funds toward slow-and-steady ideas – à la Warren Buffett – sometimes, we end up with gambling money. And in that case, speculative stocks to double your money might make sense.
Positiv
24/7 Wall Street
etwa 2 Monate alt
As the year got underway, biotechs were in focus among the notable insider purchases.
Neutral
GlobeNewsWire
etwa 2 Monate alt
WALTHAM, Mass., Jan. 11, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq:DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced the closing of its previously announced underwritten public offering of 19,722,500 shares of its common stock at a public offering price o...
Neutral
GlobeNewsWire
etwa 2 Monate alt
WALTHAM, Mass., Jan. 05, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced that Joshua Brumm, president and chief executive officer, is scheduled to present at the 42nd Annual J.P. Morgan Healthcare Conference in...
Neutral
GlobeNewsWire
etwa 2 Monate alt
WALTHAM, Mass., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq:DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced the pricing of an underwritten public offering of 17,150,000 shares of its common stock at a public offering price of $17.50 per share. Th...
Positiv
Proactive Investors
etwa 2 Monate alt
Dyne Therapeutics is off to a strong start in 2024 with positive trial data from its Duchenne muscular dystrophy (DMD) program. The company released positive initial proof-of-concept data for its two lead programs, targeting muscle diseases DM1 and DMD.

Kostenlos registrieren

aktien.guide ist das Tool zum einfachen Finden, Analysieren und Beobachten von Aktien. Lerne von erfolgreichen Investoren und triff fundierte Anlageentscheidungen. Wir machen Dich zum selbstbestimmten Investor.

Die Apple Aktie im Überblick mit Charts, aktuellen Kennzahlen, Nachrichten und Aktienanalysen.
Die besten Dividenden-Aktien in der Dividenden-Topscorer-Liste.
Aktienanalysen der besten Aktien weltweit.
Jetzt Vermögen aufbauen